大成生化科技预期年度收入及毛利分别增加约45.7%及338.1%

格隆汇
13 Mar

格隆汇3月13日丨大成生化科技(00809.HK)宣布,集团预计截至2024年12月31日止年度录得净收益(不包括税项影响),范围约在600,000,000港元至800,000,000港元,远低于集团上年度就持续经营及已终止经营业务录得的净收益(不包括税项影响)约4,178,100,000港元。集团于去年同期的已终止经营业务包括(其中包括)大成糖业控股有限公司及其附属公司的营运,于2023年12月...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10